News

IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries

SAINT LAURENT, Quebec, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical…

2 years ago

Cue Biopharma Announces Chief Medical Officer Transition

Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a…

2 years ago

IO Biotech Announces Appointment of Devin Smith as General Counsel

Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK,…

2 years ago

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide…

2 years ago

Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics

BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific…

2 years ago

12-month clinical results of a novel micro-interventional bio-stenting procedure published in the British Journal of Ophthalmology

WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Iantrek today announced the publication of 12-month clinical results of a…

2 years ago

iSpecimen to Participate in the Sequire Biotechnology Conference on February 2, 2023

LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace…

2 years ago

Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development

Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 MinuteNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) --…

2 years ago

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated…

2 years ago

Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

-- Q4 2022 revenue projected to range from $275,000 to $285,000 ---- Full year 2022 revenue projected to range from…

2 years ago